The Zantac cancer claim is barely open. Appeals are the only live path after federal and Delaware courts dismissed tens of thousands of cases.
Zantac is the brand name for ranitidine, a former prescription and over-the-counter heartburn drug. The cancer cases claim it exposed users to NDMA, which the U.S. Food and Drug Administration calls a probable human carcinogen.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
Table of Contents
- Why did Zantac leave the market?
- Why did federal courts reject the cancer link?
- What happened to the big state-court cases?
- Can you still file or join a claim?
Why did Zantac leave the market?
The U.S. Food and Drug Administration requested immediate withdrawal of all prescription and over-the-counter ranitidine on April 1, 2020.
The agency said NDMA levels could rise over time and with heat exposure, according to the FDA withdrawal announcement. The agency also said many marketed ranitidine products could expose consumers to unacceptable health risks. That safety action fueled lawsuits, but removal alone did not decide whether any individual cancer came from Zantac.
Why did federal courts reject the cancer link?
Federal litigation centered in MDL-2924 collapsed on expert proof. Judge Robin Rosenberg issued a 341-page order on Dec. 6, 2022 excluding plaintiffs' general-causation experts, leading to dismissal of about 14,000 federal cancer claims, according to the MDL Update case tracker.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Plaintiffs are waiting on an Eleventh Circuit ruling on that 2022 exclusion, expected in late 2026. A reversal could reopen federal claims. An affirmance would leave that door shut.
What happened to the big state-court cases?
GSK announced agreements on Oct. 9, 2024 with 10 plaintiff firms to resolve 93% of its U.S. state-court cases, about 80,000 cases, for up to $2.2 billion plus a $70 million qui tam settlement, according to the GSK settlement statement. The company admitted no liability. Delaware then delivered major defense wins.
The Delaware Supreme Court reversed admission of plaintiff experts on ten cancers on July 10, 2025, saying trial courts must gatekeep reliability and plaintiffs had not connected ingestion to harmful NDMA levels. In April 2026, Delaware Superior Court Judge Francis Jones granted summary judgment against more than 80,000 cases filed by Dec. 2025. No plaintiff has obtained a jury verdict finding Zantac caused cancer. Settlement payments therefore do not prove causation.
Can you still file or join a claim?
The practical opening is narrow and appeal-driven. Plaintiffs appealed the Delaware dismissal on May 13, 2026, so new filings face steep admissibility hurdles unless an appeal changes the rules. Act before your state limitations period runs, because appeals do not pause every filing deadline.
- Save proof of ranitidine use, diagnosis, dates, and prescribing pharmacy
- Ask a mass-tort lawyer whether your cancer type and state deadline fit an active appeal or settlement pool
- Do not stop prescribed treatment or assume a payout means your cancer was caused by Zantac
You Might Also Like
- Camp Lejeune Lawsuit Update: Deadlines Still Open for Claims?
- Uber Sexual Assault Lawsuit: What Riders Can Claim in 2026
- Talcum Powder Lawsuit Eligibility: What Injuries Qualify for a Claim?